José María Cruz Fernández

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek et al. · The Lancet Diabetes & Endocrinology · 2019 · 328 citations · Full text

Medicine, Cardiology, Internal Medicine +15

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Gregory G. Schwartz, Vera A. Bittner, Patricio López‐Jaramillo et al. · Journal of the American College of Cardiology · 2021 · 141 citations · Full text

Medicine, Cardiology, Pharmacology +17

Plasma cystatin C for prediction of 1-year cardiac events in Mediterranean patients with non-ST elevation acute coronary syndrome

Nevio Taglieri, Daniel Fernández‐Bergés, Wolfgang Köenig et al. · Atherosclerosis · 2009 · 63 citations

Medicine, Cardiology, Clinical Sciences +15

A comparative study of biomarkers for risk prediction in acute coronary syndrome—Results of the SIESTA (Systemic Inflammation Evaluation in non-ST-elevation Acute coronary syndrome) study

Juan Carlos Kaski, Daniel Fernández‐Bergés, Luciano Consuegra‐Sánchez et al. · Atherosclerosis · 2010 · 52 citations

Medicine, Cardiology, Internal Medicine +16

Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment

Gregory G. Schwartz, Michael Szarek, Vera Bittner et al. · Diabetes Care · 2021 · 38 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17